These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 27322682)
1. Downregulation of vimentin expression increased drug resistance in ovarian cancer cells. Huo Y; Zheng Z; Chen Y; Wang Q; Zhang Z; Deng H Oncotarget; 2016 Jul; 7(29):45876-45888. PubMed ID: 27322682 [TBL] [Abstract][Full Text] [Related]
2. Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines. Jin L; Huo Y; Zheng Z; Jiang X; Deng H; Chen Y; Lian Q; Ge R; Deng H Mol Cell Proteomics; 2014 Nov; 13(11):3138-51. PubMed ID: 25096996 [TBL] [Abstract][Full Text] [Related]
3. TET1 promotes cisplatin-resistance via demethylating the vimentin promoter in ovarian cancer. Han X; Zhou Y; You Y; Lu J; Wang L; Hou H; Li J; Chen W; Zhao L; Li X Cell Biol Int; 2017 Apr; 41(4):405-414. PubMed ID: 28150354 [TBL] [Abstract][Full Text] [Related]
4. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines. Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764 [TBL] [Abstract][Full Text] [Related]
5. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model. Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326 [TBL] [Abstract][Full Text] [Related]
6. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression. Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490 [TBL] [Abstract][Full Text] [Related]
7. Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy. He J; Yu JJ; Xu Q; Wang L; Zheng JZ; Liu LZ; Jiang BH Autophagy; 2015; 11(2):373-84. PubMed ID: 25650716 [TBL] [Abstract][Full Text] [Related]
8. Effects and mechanism of RhoC downregulation in suppressing ovarian cancer stem cell proliferation, drug resistance, invasion and metastasis. Sang XB; Sun KX; Wang LL; Chen S; Wu DD; Zong ZH; Zhao Y Oncol Rep; 2016 Dec; 36(6):3267-3274. PubMed ID: 27748937 [TBL] [Abstract][Full Text] [Related]
9. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs. Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496 [TBL] [Abstract][Full Text] [Related]
10. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways]. Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551 [TBL] [Abstract][Full Text] [Related]
11. Acquired cisplatin resistance in human ovarian A2780 cancer cells correlates with shift in taurine homeostasis and ability to volume regulate. Sørensen BH; Thorsteinsdottir UA; Lambert IH Am J Physiol Cell Physiol; 2014 Dec; 307(12):C1071-80. PubMed ID: 25252947 [TBL] [Abstract][Full Text] [Related]
12. Relationship between p-cofilin and cisplatin resistance in patients with ovarian cancer and the role of p-cofilin in prognosis. Qin Y; Li W; Long Y; Zhan Z Cancer Biomark; 2019; 24(4):469-475. PubMed ID: 30932883 [TBL] [Abstract][Full Text] [Related]
13. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121 [TBL] [Abstract][Full Text] [Related]
14. Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro. Hahne JC; Honig A; Meyer SR; Gambaryan S; Walter U; Wischhusen J; Häussler SF; Segerer SE; Fujita N; Dietl J; Engel JB Oncol Rep; 2012 Dec; 28(6):2023-8. PubMed ID: 22992944 [TBL] [Abstract][Full Text] [Related]
15. Knockdown of survivin contributes to antitumor activity in cisplatin-resistant ovarian cancer cells. Jiang L; Luo RY; Yang J; Cheng YX Mol Med Rep; 2013 Feb; 7(2):425-30. PubMed ID: 23229441 [TBL] [Abstract][Full Text] [Related]
16. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma. Ma JJ; Chen BL; Xin XY Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744 [TBL] [Abstract][Full Text] [Related]
17. Cx32 mediates cisplatin resistance in human ovarian cancer cells by affecting drug efflux transporter expression and activating the EGFR‑Akt pathway. Zhang Y; Tao L; Fan LX; Huang K; Luo HM; Ge H; Wang X; Wang Q Mol Med Rep; 2019 Mar; 19(3):2287-2296. PubMed ID: 30664215 [TBL] [Abstract][Full Text] [Related]
18. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells. Yang X; Xing H; Gao Q; Chen G; Lu Y; Wang S; Ma D Gynecol Oncol; 2005 May; 97(2):413-21. PubMed ID: 15863139 [TBL] [Abstract][Full Text] [Related]
19. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278 [TBL] [Abstract][Full Text] [Related]
20. [Regulatory effects and associated mechanisms of miR-130a molecules on cisplatin resistance in ovarian cancer A2780 cell lines]. Li NW; Wang HJ; Yang LY; Jia XB; Chen C; Wang X Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Nov; 44(6):865-70. PubMed ID: 24490491 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]